. 2020 Jun 29;111(7):2608–2619. doi: 10.1111/cas.14437

Table 2.

Clinicopathologic comparison among signal‐regulatory protein‐α (SIRPα) expression patterns in diffuse large B‐cell lymphoma

Characteristic	SIRPα^high (n = 57)		SIRPα^low (n = 58)		P value
Characteristic	No.	%	No.	%	P value
Sex (male/female)	33/24	58/42	33/25	57/43	0.91
Age (y)
Median	72		70.5
Range	29‐87		23‐85
>60	39/52	75	45/56	80	0.50
ECOG PS > 1	15/50	30	11/53	21	0.28
Extranodal sites > 1	5/51	10	6/56	11	1.00
Ann Arbor stage > 2	28/46	61	28/55	51	0.32
IPI risk group					0.38
Low (0‐2)	23/50	46	29/53	55
High (3‐5)	27/50	54	24/53	45
Hans criteria					0.91
GCB	25/53	47	27/56	48
Non‐GCB	28/53	53	29/56	52
Lymph2Cx					0.26
GCB	19/57	33	28/58	48
ABC	25/57	44	20/58	34
Unclassified	13/57	23	10/58	17
MYC translocation, positive	5/57	9	6/57	11	1.00^*
MYC protein, positive	26/57	46	29/58	50	0.64
DEL	13/57	23	14/58	24	0.87
EBER‐ISH, positive	2/57	4	2/58	3	1.00^*
Treatment					0.26^*
R‐CHOP/R‐CHOP‐like	51/57	89	56/58	97
Other chemotherapies	4/57	7	2/58	3
RT alone	2/57	4	0/58	0
Treatment response					0.66
CR/CRu	41/56	73	43/56	77
Not CR	15/56	27	13/56	23

Abbreviations: ABC, activated B‐cell; CR, complete response; CRu, uncertain complete response; DEL, double expressor lymphoma; EBER‐ISH, in situ hybridization for Epstein‐Barr virus‐encoded RNA; GCB, germinal center B‐cell; IPI, international prognostic index; PS, performance status; R‐CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; RT, radiotherapy.

Fisher’s exact test.